Citation:Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al 2013

From Cancer Guidelines Wiki

Citation


Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol 2013 Dec 2 Available from: http://www.ncbi.nlm.nih.gov/pubmed/24309370.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al 2013What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted
Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al 2013 2What is the optimal concurrent chemotherapy to be used for the treatment of limited stage small cell lung cancer with radiotherapy?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted
Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al 2013 3What is the optimal dose and fractionation schedule of thoracic radiotherapy in patients with limited stage SCLC?Dr Jeremy Ruben MBBCh (Hons), FCRadOnc (SA), FRANZCR, Mmed, MD (Monash)completed

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal systemic therapy and duration to be used for the treatment of limited stage small cell lung cancer?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal concurrent chemotherapy to be used for the treatment of limited stage small cell lung cancer with radiotherapy?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal concurrent chemotherapy to be used for the treatment of limited stage small cell lung cancer with radiotherapy?</span></span></span>»
    ]] (compare critical appraisals)
  • [[Clinical question:What is the optimal dose and fractionation schedule of thoracic radiotherapy in patients with limited stage SCLC?|
    Invalid title «<span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal dose and fractionation schedule of thoracic radiotherapy in patients with limited stage SCLC?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal concurrent chemotherapy to be used for the treatment of limited stage small cell lung cancer with radiotherapy?
Retrieved from "https://wiki.cancer.org.au/australiawiki/index.php?title=Citation:Kubota_K,_Hida_T,_Ishikura_S,_Mizusawa_J,_Nishio_M,_Kawahara_M,_et_al_2013&oldid=68632"